Respiratory & Immunology
Following the science to improve patient outcomes
Building on a 50-year heritage in respiratory care, our ambition is to transform the treatment of asthma and chronic obstructive pulmonary disease (COPD) by driving earlier, biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death.
Underpinning chronic lung diseases is an altered immune system. AstraZeneca is following the science of common pathways and underlying disease drivers from respiratory disease into immunology-driven disease areas.
The disease areas we’re targeting include rheumatology (including type 1 interferon-driven diseases such as lupus), dermatology, gastrointestinal diseases and inflammatory diseases driven by eosinophilic immune dysfunction. Our ambition is to achieve disease modification and durable remission in these diseases for millions of patients worldwide.
Senior Vice President and Global Head of Respiratory & Immunology Late Stage Development, BioPharmaceuticals R&D
Senior Vice President and Head of Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D
Join Our Team
At AstraZeneca Respiratory & Immunology, we’re driven by innovation and our commitment to make a real-life difference in patients’ lives. That difference starts with you. As one of Science Magazine’s 2018 Top Employer, we need people like you who share our passion for science and determination to meet patients’ needs around the world.
Hear from Chris
"AstraZeneca is a great place to work if you want to be challenged and if you want to have the ability to see the impact of your work towards developing medicines for patients with respiratory diseases like COPD."
Chris Miller - VP, Biometrics & Information Sciences, Respiratory & Immunology
Hear from Brad
"I have worked in immunology for over 15 years, but when I joined AstraZeneca’s global commercial organization I was especially excited by the chance to work on a potentially transformative medicine for lupus and other diseases that have had so little therapeutic advances in the past several decades. "
Brad Nohe - Head of Commercial, Head of Patient Service & Delivery, Respiratory Biologics, Respiratory & Immunology
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
Phase III/Reg. refers to assets that are in Phase III or that have been submitted for regulatory approval and may include assets that are now launched in one or more major markets.
Respiratory & Immunology (as of 29 April 2022)
We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations.
Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.
Accolate, Accoleit, Vanticon
terbutaline in a dry powder inhaler
aclidinium, a LAMA
budesonide inhalation suspension
Countering the counter-productive: it’s time for an alternative to SABA-only asthma rescue treatment
PT027, a novel fixed-dose combination of albuterol and budesonide, used as an as-needed rescue medicine, significantly reduced the risk of a severe exacerbation compared to albuterol by 27% in patients with asthma
Nirsevimab EMA regulatory submission accepted under accelerated assessment for RSV protection in all infants
Veeva ID: Z4-39160
Date of preparation: October 2021